Viviflux 20 tablets

A valid adjuvant in the primary and secondary prevention of central ischemic events and cognitive decline of vascular origin.
- DHF : dihydrofolate
- THF : tetrahydrofolate
- 5,10-METHF : 5,10-Methyltetrahydrofolate
- 5-METHF : Methyltetrahydrofolate
- MTHFR : Methyltetrahydrofolate reductase
- P5P : Pyridoxal5-phosphate
- R5P : Riboflavin5-phosphate
Folate is essential for the conversion of homocysteine ​​to methionine.
Methyltetrahydrofolate reductase (MTFHR) is the rate-limiting enzyme in the methyl cycle that catalyzes the only biochemical reaction that produces 5-methyltetrahydrofolate (Quatrefolic), useful for reducing plasma homocysteine ​​levels.
MTHFR C677T is a common MTFHR mutation with reduced catalytic activity, resulting in elevated plasma homocysteine ​​levels, a common risk factor for cardiovascular disorders. In a recent meta-analysis (published in June 2017) it was observed that patients with MTFHR C677T mutation have a 30% increased risk of developing ischemic stroke.

Ingredients
Fish oil titrated in docosahexaenoic acid (DHA), extra virgin olive oil ( Olea europa L. , fruit), edible gelatin (capsule ingredient), homotaurine, coating agents: hydroxypropyl methylcellulose, shellac; anti-caking agents: silicon dioxide; antioxidant: DL-alpha-tocopherol; stabilizer: glycerol; extracyan blueberry ( Vaccinium myrtillus L. , fruit) dry extract; colorants: iron oxide, titanium dioxide; quatrefolic acid [(6S)-5-methyltetrahydrofolic acid, glucosamine salt].

How to use
Take 1 capsule daily.

Format
20 liquid filled capsules.

Cod. FBH0002